Viridian Therapeutics, Inc. Common Stock (VRDN) is a publicly traded Healthcare sector company. As of July 27, 2026, VRDN trades at $19.27 with a market cap of $2.13B and a P/E ratio of 0.00. VRDN moved +0.10% today. Year to date, VRDN is -37.88%; over the trailing twelve months it is +10.18%. Its 52-week range spans $9.90 to $34.29. Analyst consensus is strong buy with an average price target of $33.91. Rallies surfaces VRDN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Analyst Sees 130% Upside as Viridian Hits $43 Target Post-Lumvoa Approval: Viridian Therapeutics secured FDA approval for Lumvoa to treat Thyroid Eye Disease, transitioning into a commercial-stage company and setting up direct competition with Amgen's Tepezza. Wedbush analyst Laura Chico raised the price target to $43, implying 130% upside from its prior ~$18.66 share price.
| Metric | Value |
|---|---|
| Price | $19.27 |
| Market Cap | $2.13B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.29 |
| 52-Week Low | $9.90 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $70.92M |
| Net Income | $-360.59M |
| Gross Margin | 0.00% |
13 analysts cover VRDN: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.91.